|Have Questions?||Leave a Message or Start an on-line Chat|
CD274, also called PD-L1, is expressed on activated T cells, B cells, and NKT cells. PD-L1 binds PD-1 to deliver the potent inhibitory signaling that inactivates T cells or other immune cells, which is essential to the maintenance of homeostasis of the immune systems. PD-L1 is found to be overexpressed in both solid tumors and hematologic malignancies and is important for the elusion of tumor cells from immune surveillance by inhibiting T cells functions through its receptor PD-1. High CD274 expression is usually associated with poor clinical outcomes. Accumulating evidence demonstrates that functional monoclonal antibodies of PD-L1 may potently enhance the anti-tumor effect in many cancers.The main steps in the production of this CD274 recombinant antibody include immunization; harvest of positive spleen cells; obtaining the antibody sequence by screening and sequencing; expression of the target antibody in mammalian cells; purification. The CD274 antibody was produced recombinantly and has many advantages: high reproducibility, specificity and scalability. And has been validated in ELISA, WB, IHC.
There are currently no reviews for this product.